Navigation Links
Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise
Date:5/19/2011

DEERFIELD, Ill., May 19, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") recently hired Mark Reisenauer as vice president of sales and marketing, oncology. Reporting directly to Patrick Shea, senior vice president of marketing & sales, Reisenauer will be responsible for all U.S. commercial activities supporting marketed products, the company's oncology co-promotion partners and will lead commercial planning for early stage development compounds.

"Astellas has made significant progress over the last year toward becoming a global category leader in oncology with the integration of OSI oncology and further development of the pipeline. Mark's breadth of product experience, along with his proven leadership capabilities, will be instrumental in Astellas' future success in oncology," said Shea. "We are excited to add Mark to our management team."

The majority of Mark's 20-plus year career has been committed to oncology therapies, where he has had sales and marketing responsibilities in a variety of capacities (domestic and global) at Abbott, Pharmacia, Bristol-Myers Squibb and Zeneca. Most recently, Mark has served as senior vice president and chief commercial officer of Micromet Inc. where he was involved in investor and public relations, clinical strategy, business development, and commercial launch planning.

About Astellas

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the U.S., Astellas markets products in the areas of Anti-Infectives, Cardiology, Dermatology, Neuroscience, Transplant, Oncology and Urology. For more information about Astellas Pharma US, Inc., please visit our website at www.astellas.us or follow us on Twitter at www.Twitter.com/AstellasUS.


'/>"/>
SOURCE Astellas Pharma US, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
2. Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary
3. Reportlinker Adds Astellas Pharma Inc.: PharmaVitae Profile
4. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
5. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
6. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
7. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
8. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
9. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
10. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
11. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... 2017  Researchers from DRUGSCAN ® and INC ... a live, complimentary webinar titled, "Untangling methods to tamper ... real world" on Wednesday June 28, 2017 from 12:00 ... webinar will feature interviews with recreational and dependent prescription ... techniques abusers use to prepare opioid tablets for routes ...
(Date:6/14/2017)...  In 2016, Embodied Labs took top ... and came away with $25,000 in seed-fund investment. Embodied ... as "entering the life of another" and by the ... to medical professionals in an entirely new dimension." Building ... finalist for the Department of Education,s EdSimChallenge, where they ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
Breaking Medicine Technology:
(Date:6/27/2017)... , ... June 27, 2017 , ... DrugDev ... is whether they can trust the sponsor to pay them correctly and on time. ... and CROs establish payment strategies that encourage sites to work on their studies. , ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... payment solution for many of the health care industry’s hospitals and provider groups, ... patient financing portal for select customers. Parasail Health is a San Francisco health-finance ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Association’s SUNucate efforts, Louisiana became the sixth state to pass legislation which ... Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article ... reach a staggering $6.81 billion by the year 2024 according to a new report. ... rate than those made from titanium. Los Angeles area clinic Beverly Hills Periodontics & ...
(Date:6/27/2017)... ... June 27, 2017 , ... The Kelahan ... planning services to residents of southern New Hampshire, is teaming up with the ... fight hunger and homelessness in the region. , New Horizons for New Hampshire ...
Breaking Medicine News(10 mins):